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ABSTRACT 52 
 53 
There is much uncertainty as to how fungal disease is diagnosed and characterized in patients with 54 
cystic fibrosis (CF).  A 19 question anonymous electronic questionnaire was developed and 55 
distributed to ascertain current practice in clinical microbiology laboratories providing a fungal 56 
laboratory service to CF centres in the UK.  Analyses of responses identified the following: (i) 57 
current UK laboratory practice, in general, follows the current guidelines, but the scope and 58 
diversity of what is currently being delivered by laboratories far exceeds what is detailed in the 59 
guidelines; (ii) there is a lack of standardization of fungal tests amongst laboratories, outside of the 60 
current guidelines; (iii) both the UK CF Trust Laboratory Standards for Processing Microbiological 61 
Samples from People with Cystic Fibrosis and the US Cumulative Techniques and Procedures in 62 
Clinical Microbiology (Cumitech) Guidelines 43 Cystic Fibrosis Microbiology, need to be updated 63 
to reflect both new methodological innovation, as well as better knowledge of fungal disease 64 
pathophysiology in CF; (iv) there is a need for clinical medicine to decide upon a stratification 65 
strategy for the provision of new fungal assays that will add value to the physician in the optimal 66 
management of CF patients; (v) there is also a need to rationale what assays should be performed at 67 
local laboratory level and those which are best served at National Mycology Reference Laboratory 68 
level; and (vi) further research is required in developing laboratory assays, that will help ascertain 69 
the clinical importance of “old” fungal pathogens, as well as “emerging” fungal pathogens.70 
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations of the cystic fibrosis 71 
transmembrane conductance regulator (CFTR) gene, which is located on the long arm of human 72 
chromosome 7 [1]. All disease-causing mutations in the CFTR gene prevent the chloride ion 73 
channel from functioning properly, leading to a blockage of the movement of salt and water into 74 
and out of cells.  As a result of this blockage, cells that line the passageways of the lungs, pancreas 75 
and other organs produce abnormally thick, sticky mucus which obstructs the airways and glands, 76 
causing the characteristic signs and symptoms of CF. The most life-threatening complications, in 77 
CF patients, are pulmonary inflammation and infection, from bacteria and fungi becoming trapped 78 
in the thick, tenacious secretions in the airways, resulting in a vicious cycle of infection and 79 
inflammation. Chronic lung infection is responsible for more than 90% of deaths in adults with CF 80 
[2]. 81 
Although the predominant infections associated with the CF lung are associated with bacteria, 82 
yeasts and filamentous fungi are frequently recovered from respiratory specimens from these 83 
patients, especially with the increased use of B. cenocepacia selective agars, which support fungal 84 
detection. These bacterial selective media contain high concentrations of several antibiotics, 85 
enhancing growth of highly antibiotic-resistant bacterial species, including B. cenocepacia, which 86 
will inadvertently support the growth of fungi. However, it is important that laboratories do not rely 87 
solely on these for the isolation of fungi, but instead employ fungal selective agar to attempt the 88 
isolation of these eucaryotes. 89 
There is a growing awareness amongst CF physicians of the importance of fungal infections in 90 
patients with CF, largely due to : (i) the increasing incidence of fungal disease in CF patients; (ii) 91 
emerging novel mechanisms of fungal pathophysiological disease, for example, Aspergillus 92 
bronchitis; (iii) the limited number of effective therapies that are available or their association with 93 
dose-limiting toxicities; (iv) the fact that fewer symptoms bring the infection to the attention of the 94 
patient and physician early on; and (v) the difficulties to make an early diagnosis because of the 95 
lack of sensitive tests for the detection of invasive fungal infections [3]. Culturing Aspergillus 96 
fumigatus, per se, is not an indication for treatment but this fungus has a wide range of clinical 97 
presentations and when combined with the presence of co-habiting bacterial pathogens, such as 98 
Pseudomonas aeruginosa, makes it more difficult to attribute clinical significance to the presence of 99 
the fungus.  Reliable laboratory detection of fungi is thus the cornerstone of subsequent clinical 100 
considerations. 101 
Currently it is difficult to estimate the prevalence of fungal infections in patients with CF. This is 102 
due mainly to a lack of monitoring of the presence of fungi in microbiological cultures of sputum, 103 
in most CF registries/databases in the UK and Europe. The US Cystic Fibrosis Foundation (CFF) 104 
Registry data, however, indicates an approximate doubling of prevalence of fungi being detected in 105 
the sputum of patients with CF, from 1995 through 2005, rising from approximately 6% in 1995 to 106 
approximately 13% in 2005.  Such a rise as this could be the cumulative effect of the ad hoc 107 
introduction of novel and improved laboratory methods, as well as greater awareness of fungi 108 
disease in CF. In the absence of such data, the clinical significance of fungi is indicated mainly 109 
through reports in the scientific/medical literature. To date, the majority of reports have included 110 
clinically significant fungi such as Aspergillus spp., Scedosporium species and Exophilia 111 
dermatitidis [3]. 112 
Evolving laboratory technology and methodologies aids in the isolation, identification and 113 
characterization of aetiological agents of fungal disease in CF patients.  Coupled with this, various 114 
laboratory guidelines exist to guide Clinical Microbiology Laboratories, in the employment of 115 
suitable techniques to employ, to support laboratory workup of respiratory specimens, and to guide 116 
clinicians in patients’ management.  It was therefore the aim of this study to examine how a cohort 117 
of NHS Clinical Microbiology Service Laboratories, supporting CF Centres in the UK were 118 
performing CF fungal diagnosis. 119 
 120 
A 19 question anonymous electronic questionnaire was developed and posted on the SurveyGizmo 121 
platform for completion (see online Supplementary material).  This questionnaire is also available at 122 
the following link: www.surveygizmo.eu/s3/90008906/Fungal-Laboratory-Questionnaire-for-123 
Cystic-Fibrosis 124 
The questionnaire was designed in four sections, exploring NHS service laboratory aspects of: (i) 125 
fungal isolation; (ii) fungal identification; (iii) fungal characterization; and (iv) promoting best 126 
practice. The questionnaire was distributed amongst NHS Consultant Respiratory Physicians and 127 
NHS Consultant Paediatricians involved in the clinical care of patients with CF at recognised UK 128 
CF Centres. A request was made to 94 paediatric and adult CF consultants in the UK to forward the 129 
questionnaire onto their Consultant Microbiologist, who supports the CF Centre, in terms of NHS 130 
Microbiology Laboratory Service provision. Questionnaires were duly completed and returned via 131 
the SurveyGizmo platform for analyses. 132 
 133 
Responses to the questionnaire were received from 11 publically-funded NHS Clinical 134 
Microbiology laboratories in the UK, supporting either a CF Adult Service or a CF Paediatric 135 
Service. Collated responses to the specific questions asked are shown in Table 1. 136 
 137 
The goal of any clinical microbiology laboratory supporting the routine processing of sputum and 138 
other respiratory specimens from CF patients, is to provide a robust and effective service, in a 139 
timely and cost effective manner. Any assays that are performed need to add clinical value and aid 140 
the physician in the clinical decision-making process.  Driving forces, namely the development of 141 
novel techniques of isolation and characterization of fungi and new insights into the 142 
pathophysiology of fungal disease in CF patients, make the methodological techniques to be in a 143 
constant state of evolution, thus requiring periodic rationalization to ensure NHS routine service 144 
fungal assays are keeping pace with methodological innovation, as well as emerging knowledge on 145 
disease driving what assays to optimally employ. 146 
Currently, there are at least two laboratory standards in the UK and US, respectively namely the UK 147 
CF Trust Laboratory Standards for Processing Microbiological Samples from People with Cystic 148 
Fibrosis [4] and the US Cumulative Techniques and Procedures in Clinical Microbiology 149 
(Cumitech) Guidelines 43 Cystic Fibrosis Microbiology [5].  Many countries may have their own 150 
national standards in place.  A comparison of these standards is shown in Table 2.  When we 151 
compare the findings of this questionnaire, against these current guidelines for the laboratory 152 
processing of sputum for fungi from CF patients, responses to this questionnaire were generally 153 
within compliance of these guidelines. This study indicated that many laboratories are currently 154 
performing several more assays than are presently listed in the laboratory guidelines, with a high 155 
degree of non-standardization in assays not defined in the guidelines. Our questionnaire showed that 156 
most laboratories are employing basic fungal detection media, mainly SDA with or without 157 
antibiotics. Most laboratories are cautious about employing enhanced specific fungal culture media, 158 
such as DRBC-benomyl, Sce-Sel+ or Scedo-Select III, to aid with the isolation of fungi from CF 159 
sputum; none were using these recently described media [6]. 160 
Whilst this study received responses from 11 NHS Clinical Microbiology laboratories, this should 161 
not be interpreted as being fully reflective of practice in all NHS laboratories.  However, we believe 162 
that the responses received from these 11 laboratories are a microcosm of UK laboratory practice 163 
and a reasonable reflection of what UK laboratories are currently doing. 164 
The biggest challenge resulting from analysis of this questionnaire is the lack of standardization of 165 
methods across these laboratories.  Previously, Borman and colleagues [7] investigated the 166 
consequences of the lack of standardization of fungal methodologies across eight laboratories and 167 
concluded that without more sophisticated molecular methods, the aetiological role of “rarer” 168 
filamentous fungi in pulmonary exacerbations will remain hidden. 169 
Most recently, the February 2018 issue of Mycopathologia (Volume 183; Issue 1) contains 25 170 
articles which are highly relevant to this area.  In particular, the paper by Chen and colleagues [8] 171 
discusses the challenges in laboratory detection of fungal pathogens in the airways of CF patients.  172 
In this article, the authors highlight and discuss in detail the repertoire of available mycological 173 
laboratory techniques (cultural and molecular methods) to support accurate isolation, identification 174 
and characterization of fungal organisms from CF respiratory specimens and conclude that 175 
guidelines for standardized processing of respiratory specimens are urgently needed.  Following on 176 
from this call for urgent standardization of methods, the paper by Coron and colleagues [9] takes on 177 
this challenge to standardize cultural/isolation methods with the “MucoFong” program, whereby 178 
sputa from 243 CF patients from seven CF centres in France were studied over a 15 month period.  179 
Six fungal culture media were compared and the study concluded that four of these media, namely 180 
CHROMAgar Candida medium incubated at 37°C, Sabouraud dextrose agar with chloramphenicol 181 
and gentamicine at 25°C, Sabouraud dextrose agar with chloramphenicol and cycloheximide at 182 
37°C and erythritol agar at 27°C should be employed to optimally recover fungal pathogens from 183 
CF respiratory specimens.  Initiatives such as the MucoFong program are extremely valuable as 184 
they present an evidence-base for laboratories to move forward confidently in the knowledge that 185 
they are providing an optimal service for the patients.  186 
 187 
The current study highlights the following: 188 
(i) that current UK laboratory practice, in general, follows the current guidelines, but that the scope 189 
and diversity of what is currently being delivered by laboratories far exceeds what is detailed in the 190 
guidelines; 191 
(ii) there is a lack of standardization of fungal tests amongst laboratories, outside of the current 192 
guidelines; 193 
(iii) as a result, both the UK CF Trust Laboratory Standards for Processing Microbiological 194 
Samples from People with Cystic Fibrosis [4] and the US Cumulative Techniques and Procedures in 195 
Clinical Microbiology (Cumitech) Guidelines 43 Cystic Fibrosis Microbiology [5], need to be 196 
updated to reflect both new methodological innovations, as well as better knowledge of fungal 197 
disease pathophysiology in CF; 198 
(iv) there is a need for clinical medicine to decide upon a stratification strategy for the provision of 199 
new fungal assays with added value to guide physicians for an optimal management of CF patients; 200 
(v) there is a need to rationale what assays may be performed at local laboratory level and those 201 
which are best served at National Mycology Reference Laboratory level; 202 
and (vi) further research is required in developing laboratory assays, that will help ascertain the 203 
clinical importance of “old” fungal pathogens, as well as “emerging” fungal pathogens. 204 
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  240 
Table 1:  Responses to CF laboratory fungal questionnaire from 11 UK NHS Microbiology 241 
Service Laboratories 242 
 243 
 
Survey question 
 
Survey response 
 
 
 
FUNGAL ISOLATION 
 
 
1. Under which of the following 
circumstances does your lab attempt to 
isolate fungi from CF patients: 
On all submitted specimens 
Only on request from the submitting 
clinician 
Other (e.g. high risk patients / post 
transplant) 
Eleven (91.7%) respondents answered on all submitted specimens and one 
respondent added ‘any specimen except cough swabs’. 
2. Do you routinely use a selective medium 
for isolation of fungi from CF specimens? 
 
 
Ten respondents (91%) routinely use the fungal selective medium, Sabouraud 
(SAB), for isolation of fungi from CF specimens. There was wide variation in the 
incubation time and temperature employed, including: 
 
SAB for 5 days 
SAB at 30 and 37°C 
SAB for 2 days at 37°C + 5 days at 30°C 
SAB + chloramphenicol at 30°C + 37°C for 48 hours + 5 days 
SAB in CO2 at 37°C for 5 days 
SAB + gentamicin + chloramphenicol at 37°C for 5 days 
SAB at 35-37°C for 48 hours. 
 
No laboratory reported using other CF selective media. 
3. Does your laboratory employ molecular 
methods for the detection of fungi from CF 
specimens? (either in-house or referral 
outside) 
Two (18.2%) laboratories employ molecular methods. 
4. Does your laboratory employ other 
methods, (e.g. precipitin testing, 
galactomannan), different to Q2 and Q3 
above? 
Eight (72.7%) laboratories employ other methods (e.g. precipitin testing, 
galactomannan). Four of these would refer to another lab for testing, while one 
can do tests as special request, although their Aspergillus PCR and 
susceptibility testing are referred to the Mycology reference lab. 
FUNGAL IDENTIFICATION  
5. On isolation of a fungus from a CF 
specimen, which of the following do you 
attempt to identify? in-house or via a 
Mycology Reference laboratory 
All of the 11 respondents attempt to identify all filamentous fungi that are 
recovered, and 3 (27.3%) attempt for yeasts 
6. What methods of fungal identification do 
you employ to achieve this? 
Six (54.5%) use in-house and 3 (27.3%) refer to the Mycology Reference 
Laboratory. The remaining two respondents commented, ‘a combination of 
conventional mycology in-house or reference laboratory for non-Candida’ and, 
‘some ID in-house via conventional phenotypic methods, others sent to 
reference laboratory’. 
Of those who had answered In-house, three use conventional mycology, one 
uses conventional and MALDI-TOF mass spectrometry, one uses microscopy, 
18S rDNA sequencing and the final comment was, ‘phenotypic, then 18S rDNA 
sequencing if no identification or uncertain identification (then reference 
laboratory if confirmation required). 
7. What is your laboratory's practice for 
isolating, identifying and testing anti-fungal 
susceptibility on Candida spp and/or other 
yeasts?  
- Identification of black yeasts: 7/11 laboratories 
- Identification of other yeasts: 2/11 (by MALDI-TOF mass spectrometry) 
- Antifungal susceptibility testing :  
 Routinely performed on all yeast species 0/11 
 Performed only on non-albicans yeast species: 5/11  
 Susceptibility testing performed by reference laboratory: 7/11. 
- For in house in vitro susceptibility testing: 3/11 use VITEK 2 and 1/11 uses 
Yeast One sensititre plates 
CHARACTERIZATION OF 
FILAMENTOUS FUNGI 
 
8 & 9. Do you routinely perform antifungal 
susceptibility testing on any/all of the fungal 
isolates obtained from CF specimens. 
Seven (63.6%) of nine respondents do not routinely perform antifungal 
susceptibility testing on any/all of the fungal isolates from CF specimens. 
Two (18.2%) do, stating ‘MIC tested on isolates from BAL samples’ and, ‘Yeasts 
if treatment clinically indicated’. 
If so,  
10. Which Mycology Reference Lab is ? 
Do they charge for this service?  
How much per specimen? 
What is their turnaround time? 
 
Six laboratories use the Bristol Reference Laboratory and one uses the 
Manchester Reference Laboratory. Five reported that they are charged for the 
service, while one comment stated that some tests are not charged. None of 
the respondents knew the cost per specimen. The turnaround time responses 
varied from 5 days to two weeks, depending on the isolate. 
11. Which antifungal agents would you like 
tested?  
(Either in-house or via Mycology Reference 
Laboratory) 
Ten (90.9%) would like voriconazole tested, 9 (81.8%) indicated ambisome and 
itraconazole, 7 (63.6%) fluconazole and caspofungin, 5 (45.5%) posaconazole, 
4 (36.4%) micafungin, 2 (18.2%) anidulafungin and isavuconazole and one 
chose abelcet. Additional comments were: ‘we test amphotericin not the 
formulations’ and, ‘it depends on what we are sending and what is available in 
our formulary’ 
 
12. Do you perform any further fungal 
characterisation on the isolates? (e.g. 
molecular typing)  
 
None of the 11 of the respondents perform any other fungal characterization test 
(e.g. molecular typing) on the isolates 
13. What is your laboratory policy on the 
storage/preservation of CF fungal isolates?  
 
 
 
 
 
Would you be willing to archive your CF 
fungal isolates in a CF strain repository for 
sharing with others? 
Two (18.2%) laboratories reported (18.2%) the all fungal isolates were 
preserved, 3 (27.3%) reported that nothing was preserved and the remainder 
(6) left additional comments including storage of unusual isolates, storage of 
new isolates, keeping clinical isolates for a limited time due to storage capacity, 
keeping by specific request (beads for 2 years) and those that have been 
referred to the Reference Laboratory. 
 
Nine (90%) laboratories reported they would be willing to archive CF fungal 
isolates in a CF strain repository for sharing with others. The others responded 
negatively, citing very limited on-site capacity, however one responded that they 
would unwilling to archive on site but happy to send to a central fungal 
repository. 
  244 
PROMOTING BEST PRACTICE 
 
 
 
14. Would your laboratory have the capacity 
to handle additional requests for fungal 
work-up from the CF clinical team?  
 
 
Would you be willing to change your CF 
fungal work-up if presented with 'Best 
Practice Guidelines'? 
 
Seven (63.6%) laboratories reported they would have the capacity to handle 
additional requests for fungal work-up from the CF team, and 2 (18.2%) stated 
they would not have capacity. Comments from the respondents highlighted that 
funding would be the main barrier to taking on additional requests.  
 
All eleven respondents stated they would be willing to change their CF fungal 
work-up if presented with ‘Best Practice Guidelines.’ 
 
Lack of financial resources was reported as the main issue with changing 
practice and one comment stated, ‘CF samples are expensive and not properly 
resourced’. 
 
19. Would you support the establishment of 
a National CF Mycology Reference Service 
/ Laboratory? 
 
(This could take the form of a "Virtual 
Reference Laboratory", with several 
specialist Mycology laboratories providing 
individual specific assays under a service 
level agreement) 
 
Seven of the ten respondents said they would support this and one person 
would not. Comments given were, ‘not sure if there is a need for this’, ‘possibly 
if supported by evidence’ and ‘undecided –(current Mycology Reference Lab do 
a good job and unsure of the need for duplication)’. 
 245 
  246 
Table 2:  Comparison of UK CF Trust Laboratory Standards for Processing Microbiological 247 
Samples from People with Cystic Fibrosis and the US Cumulative Techniques and 248 
Procedures in Clinical Microbiology (Cumitech) Guidelines 43 Cystic Fibrosis Microbiology, 249 
for the examination of fungi from patients with CF. 250 
 251 
 
CF Trust Consensus Guidelines 
 
US Cumitech Guidelines 
 
  
Fungal infections have become more prevalent in 
people with CF in recent years. Infection with Aspergillus 
spp. has long been recognised as a problem in CF, 
usually presenting as allergic bronchopulmonary 
aspergillosis. Recently it has been suggested that 
Aspergillus infection can cause respiratory 
exacerbations by stimulating a fungal-associated 
bronchitis that responds to specific antifungal therapies. 
Other fungi are increasingly recognised as 
complications of CF care e.g. Scedosporium 
apiospermum and Wangiella (now called Exophiala) 
dermatitidis. 
 
Sabouraud medium should be used to enhance the 
recovery of fungi from respiratory samples of people with 
CF. 
 
The addition of appropriate antibiotics reduces 
contamination rates with P. aeruginosa. 
 
Plates should be incubated at 35-37°C in air and 
examined after overnight incubation and after at least 
another 24 hours. Prolonging cultures up to seven days 
and at different temperatures (e.g. 22°C) may increase 
yield. 
 
Correct identification of Aspergillus species is important 
as some are resistant to amphotericin, e.g. A. versicolor, 
A. nidulans, A. lentulus. Itraconazole-resistant 
Aspergillus fumigatus has been described and multiple 
triazole resistance has also been reported. If a patient 
has had prior treatment with azoles, susceptibility testing 
may therefore be warranted 
 
In people with CF, the repeated isolation of Aspergillus 
spp., in spite of long-term treatment with antifungal 
drugs (e.g. itraconazole or voriconazole as steroid 
sparing treatment for ABPA), may indicate the need for 
referral of isolates to a reference laboratory for 
susceptibility testing. 
 
Routine culture for fungi is not recommended for CF 
patients, although the organisms may grow on bacterial 
isolation media. When fungal isolation is attempted, it is 
recommended that antibacterial agents with 
antipseudomonal activity be incorporated into the medium. 
 
Allergic bronchopulmonary Aspergillosis (ABPA) 
laboratory diagnosis may be aided by: Serum 
immunoglobulin E (IgE) concentration of 500 IU/ml and the 
presence of IgE antibodies to A.fumigatus and/or IgG 
antibodies to A. fumigatus. 
 
Aspergillus spp. should be isolated on fungal media 
containing gentamicin at 30°C for 3 weeks in ambient air.  
Identification should adopt conventional identification 
methods. Susceptibility tests are not applicable. 
 
The major fungal pathogen in CF patients is Aspergillus. It 
can grow on several of the selective bacterial media. 
Aspergillus can chronically infect or colonize CF patients. 
When Aspergillus is first detected in a bacterial culture, it 
should be identified to the species level and reported. After 
the initial isolation, the frequency of identification and 
reporting should be based on clinician expectations and 
needs. When fungal cultures are specifically requested for 
CF patients, selective fungal media are required because 
of the potential for bacterial over-growth, especially with P. 
aeruginosa. Selective fungal media containing gentamicin, 
amikacin, or ciprofloxacin should be used because of their 
activity against strains of P. aeruginosa and because 
media containing these antimicrobials will enhance the 
recovery of molds from CF respiratory specimens. 
Although Candida species are frequently recovered from 
CF respiratory specimens, there is no evidence that these 
organisms play a role in chronic CF lung disease. 
Therefore, Candida should not be reported for respiratory 
cultures from CF patients. 
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